These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2280 related articles for article (PubMed ID: 20399983)
1. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
5. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. Song QB; Wang Q; Hu WG World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888 [TBL] [Abstract][Full Text] [Related]
6. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
7. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465 [TBL] [Abstract][Full Text] [Related]
8. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985 [TBL] [Abstract][Full Text] [Related]
9. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426 [TBL] [Abstract][Full Text] [Related]
10. Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer. Wang L; Chen X; Li W; Sheng Z Anticancer Drugs; 2012 Feb; 23(2):155-60. PubMed ID: 21955998 [TBL] [Abstract][Full Text] [Related]
11. Integration of novel agents in the treatment of colorectal cancer. Iqbal S; Lenz HJ Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512 [TBL] [Abstract][Full Text] [Related]
12. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Khattak MA; Martin H; Davidson A; Phillips M Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296 [TBL] [Abstract][Full Text] [Related]
14. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037 [TBL] [Abstract][Full Text] [Related]
15. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083 [TBL] [Abstract][Full Text] [Related]
16. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097 [TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747 [TBL] [Abstract][Full Text] [Related]
18. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
19. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis. Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]